The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
M. Kittaneh
No relevant relationships to disclose
A. J. Montero
No relevant relationships to disclose
K. Kovacs
No relevant relationships to disclose
V. D. Guardiola Amado
No relevant relationships to disclose
A. M. Flores
No relevant relationships to disclose
A. Ferrell
No relevant relationships to disclose
M. Vulfovich
No relevant relationships to disclose
M. D. Pegram
Consultant or Advisory Role - Bristol-Myers Squibb
P. W. Benedetto
No relevant relationships to disclose
C. M. S. Rocha Lima
No relevant relationships to disclose
J. R. Merchan
Research Funding - Bristol-Myers Squibb; Pfizer